Stockscreener 앱 받기
2.46
0.40%
-0.01
시간 외 거래:
2.43
-0.03
-1.22%
전일 마감가:
$2.47
열려 있는:
$2.44
하루 거래량:
479.02K
Relative Volume:
0.57
시가총액:
$386.30M
수익:
$79,600
순이익/손실:
$-48.26M
주가수익비율:
-4.998
EPS:
-0.4922
순현금흐름:
$-28.24M
1주 성능:
+11.31%
1개월 성능:
+20.59%
6개월 성능:
+53.75%
1년 성능:
+72.03%
1일 변동 폭
$2.42
$2.525
1주일 범위
$2.24
$2.525
52주 변동 폭
$1.33
$2.53
Inhibikase Therapeutics Inc Stock (IKT) Company Profile
명칭
Inhibikase Therapeutics Inc
전화
(302) 295-3800
주소
1000 N. WEST STREET, SUITE 1200, WILMINGTON
Compare IKT vs VRTX, REGN, ARGX, RVMD, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
IKT
Inhibikase Therapeutics Inc
|
2.46 | 369.03M | 79,600 | -48.26M | -28.24M | -0.4922 |
VRTX
Vertex Pharmaceuticals Inc
|
523.91 | 121.57B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
808.05 | 69.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
866.11 | 55.61B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
206.97 | 39.98B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
359.00 | 33.81B | 5.76B | 514.49M | 1.10B | 4.4813 |
Inhibikase Therapeutics Inc Stock (IKT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-04 | 개시 | Ladenburg Thalmann | Buy |
| 2026-01-21 | 개시 | BofA Securities | Buy |
| 2025-12-26 | 개시 | H.C. Wainwright | Buy |
| 2025-12-11 | 개시 | Cantor Fitzgerald | Overweight |
| 2025-02-12 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
Inhibikase Therapeutics Inc 주식(IKT)의 최신 뉴스
Inhibikase Therapeutics Inc (IKT) Valuation: PE, PB & Fair Value Analysis - TradingKey
Inhibikase Therapeutics Inc (IKT) Cash Flow - TradingKey
Inhibikase Therapeutics Inc (IKT) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Inhibikase Therapeutics, Inc. $IKT Position Boosted by Kalehua Capital Management LLC - MarketBeat
Inhibikase Therapeutics, Inc. Revenue Breakdown – BOATS:IKT - TradingView
IKT|Inhibikase Therapeutics Inc|Price:2.330| - TradingKey
TradingKey - TradingKey
IKT|Inhibikase Therapeutics Inc|Price:2.355|Chg%:+0.025 - TradingKey
Inhibikase Therapeutics Inc (IKT) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Inhibikase Therapeutics (NASDAQ:IKT) Rating Increased to Sell at Wall Street Zen - MarketBeat
Inhibikase Therapeutics Inc (IKT) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
RA CAPITAL MANAGEMENT, L.P. Acquires 25 Million Shares in Inhibi - GuruFocus
Inhibikase Therapeutics (IKT) Secures Orphan Drug Designation fr - GuruFocus
$Inhibikase Therapeutics (IKT.US)$ - Moomoo
Inhibikase Gains FDA Orphan Drug Status for IKT-001 - TipRanks
Inhibikase Therapeutics (IKT) Secures Orphan Drug Designation from FDA - GuruFocus
Inhibikase Therapeutics Announces FDA Orphan Drug Designation Granted to IKT-001 for the Treatment of PAH - The Manila Times
Inhibikase's IKT-001 gets FDA orphan designation for PAH, about 50,000 Americans - Stock Titan
Inhibikase Therapeutics | PRE 14A: Preliminary proxy statements relating to merger or acquisition - Moomoo
Frontier tech research, news & data - MLQ.ai
RA Capital Management files initial beneficial ownership statement in Inhibikase Therapeutics - Bitget
Inhibikase Therapeutics (NASDAQ:IKT) Rating Lowered to Strong Sell at Wall Street Zen - MarketBeat
RA Capital discloses 25M-share stake in Inhibikase Therapeutics (IKT) - Stock Titan
RA Capital (NASDAQ: IKT) reports 25M-share, 15.9% stake in Inhibikase - Stock Titan
IKT Receives FDA Orphan Designation for Pulmonary Arterial Hyper - GuruFocus
Inhibikase Therapeutics Announces Sale of $50 Million of Shares through its At-the-Market Facility - marketscreener.com
Inhibikase Therapeutics Announces Sale of $50 Million of Shares Through its At-the-Market (ATM) Facility - Sahm
Inhibikase raises $50M to fund PAH program - TipRanks
Inhibikase Therapeutics, Inc. (NASDAQ:IKT) Given Average Rating of "Buy" by Brokerages - MarketBeat
Inhibikase raises $50 million through stock sale to RA Capital By Investing.com - Investing.com Nigeria
Inhibikase Therapeutics Shares Rise on $50M At‐the‐Market Share Sale - Moomoo
Inhibikase raises $50 million through stock sale to RA Capital - Investing.com
Inhibikase Therapeutics Sells $50M of Stock to RA Capital via ATM Facility - TradingView
Inhibikase Therapeutics (NASDAQ:IKT) Rating Increased to Strong-Buy at LADENBURG THALM/SH SH - MarketBeat
Inhibikase Therapeutics (Nasdaq: IKT) sells 25M shares for $50M cash - Stock Titan
Inhibikase Therapeutics (NASDAQ:IKT) Shares Down 3.9%Here's What Happened - MarketBeat
Inhibikase Therapeutics Q1 2026 Earnings: EPS Beat Fails to Lift Stock as Cash Burn ContinuesEPS Surprise History - dars.gov.et
Inhibikase Therapeutics Inc. (IKT) Q1 2026 Earnings: Narrowed Loss Beats Estimates as Pipeline Progress Continues - dars.gov.et
INHIBIKASE THERAPEUTICS INC (IKT) Stock Chart - ChartMill
Inhibikase Therapeutics Inc (NASDAQ: IKT) Share Price, IKT Stock News, IKT Share Price & Updates - Kalkine
Inhibikase Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Inhibikase awards stock options to 7 new hires under inducement plan - Stock Titan
Director at Inhibikase (NASDAQ: IKT) receives 155K stock options grant - Stock Titan
Inhibikase (IKT) director receives 155,000 stock options at $1.91 strike price - Stock Titan
Inhibikase (NASDAQ: IKT) investors back 3M-share plan boost and officer protections - Stock Titan
Inhibikase Therapeutics, Inc.(NasdaqCM:IKT) dropped from Russell 3000E Growth Benchmark - marketscreener.com
Inhibikase Therapeutics, Inc.(NasdaqCM:IKT) dropped from Russell 3000 Growth Benchmark - marketscreener.com
Inhibikase Therapeutics, Inc.(NasdaqCM:IKT) dropped from Russell 2500 Growth Benchmark - marketscreener.com
Enterprise value to EBITDA forward of Inhibikase Therapeutics, Inc. – NASDAQ:IKT - TradingView
Inhibikase Therapeutics, Inc.(NasdaqCM:IKT) dropped from Russell 2000 Growth Benchmark - marketscreener.com
Enterprise value to EBITDA forward of Inhibikase Therapeutics, Inc. – BOATS:IKT - TradingView
Inhibikase Therapeutics Inc (IKT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Inhibikase Therapeutics Inc 주식 (IKT) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Sands Capital Life Sciences Pu | 10% Owner |
Nov 21 '25 |
Buy |
1.45 |
2,068,965 |
2,999,999 |
13,018,965 |
0.82%
1.54%
자본화:
|
볼륨(24시간):